The Future is Bright
Guest Dr. Jonathan Barratt talks with us about two new treatments for IgA Nephropathy (IgAN) –the first specifically designed and approved for the management of IgAN.
TARPEYO® (budesonide, delayed release capsules) was approved by the U.S. Food and Drug Administration (FDA) in December 2021 and FILSPARI™ (sparsentan) gained approval earlier this year. Both are prescription medicines used to lower levels of protein in the urine (proteinuria) in adults with IgAN who are at risk of their disease progressing quickly.
Dr. Barratt, who is a nephrologist at the University of Leicester in the UK, says their approvals mark a pivotal turning point for many people with IgAN and their caregivers. As principal investigator for many international randomized controlled clinical trials in IgAN, he has seen major advancements in treatments for IgAN, with many more clinical trials underway to study additional therapies and deepen our understanding of the root cause of the disease.
He encourages patients to learn about their IgAN, and ask about new treatments, including the potential benefits and side effects, as well as available clinical trials.